Disruption of the CD47/SIRPα axis with specific mAbs may promote cancer cell elimination by macrophages, and it is a potential immunotherapeutic strategy recently described for different cancers, including SCLC and NSCLC (24, 26, 47–49). Here, SIRPA is linked to small cell lung carcinoma.